NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-262-2005-0-IE-49 Mutated Pseudomonas Exotoxins with Reduced Antigenicity IE EP 15191391.0 Issued
NCI E-262-2005-0-IT-50 Mutated Pseudomonas Exotoxins with Reduced Antigenicity IT EP 15191391.0 Issued
NCI E-262-2005-0-NL-51 Mutated Pseudomonas Exotoxins with Reduced Antigenicity NL EP 15191391.0 Issued
NIAID E-052-2017-0-US-01 Trispecific Binding Protein US 62/246,113 Abandoned
NLM E-111-2016-2-US-01 Novel CRISPR Enzymes And Systems US 62/245,273 Abandoned
NLM E-111-2016-3-US-01 Novel CRISPR Enzymes And Systems US 62/245,278 Abandoned
NLM E-111-2016-4-US-01 Novel CRISPR Enzymes And Systems US 62/285,349 Abandoned
NCI E-266-2015-0-US-01 Process For Preparing Z-endoxifen Of High Purity US 62/245,012 Abandoned
NEI E-210-2015-0-US-01 A Method For Treating Retinal Degeneration By Disrupting A Transcription Factor In Photoreceptors US 62/245,186 Abandoned
NLM E-110-2016-1-US-01 Novel CRISPR Enzymes And Systems US 62/245,264 Abandoned
NLM E-111-2016-1-US-01 Novel CRISPR Enzymes And Systems US 62/245,271 Abandoned
NCI E-039-2017-0-US-01 Phenyl Indole Allosteric Inhibitors Of P97 ATPase US 62/244,497 Abandoned
NICHD E-062-2015-0-US-01 Codon-optimized Reduced-size ATP7A CDNA and Uses for Treatment of Copper Transport Disorders US 62/244,594 Abandoned
NCI E-085-2013-0-CN-07 Methods for Producing Enriched Populations of Tumor Reactive T Cells from Peripheral Blood CN National Stage 201380075806.0 Issued
NIAID E-074-2011-2-US-07 Infectious Hepatitis E Virus Genotype 3 Recombinants US DIV 14/918,466 9850468 Issued PDF
NCI E-059-2013-0-CN-05 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor CN National Stage 201380075798.X Pending
NCI E-084-2016-0-US-01 Methods Of Preparing T Cells For T Cell Therapy US 62/224,036 Abandoned
NCI E-066-2015-0-US-01 Biodosimetry Analysis US 62/244,044 Abandoned
NCI E-013-2016-0-US-01 Methods of Producing T Cell Populations Using AKT Inhibitors US 62/243,834 Abandoned
NHLBI E-253-2014-0-IE-09 Segmented Metallic Guidewires IE EP 15787824.0 Issued
NHLBI E-253-2014-0-GB-08 Segmented Metallic Guidewires GB EP 15787824.0 Issued
NHLBI E-253-2014-0-CH-05 Segmented Metallic Guidewires CH EP 15787824.0 Issued
NHLBI E-253-2014-0-FR-07 Segmented Metallic Guidewires FR EP 15787824.0 Issued
NHLBI E-253-2014-0-DE-06 Segmented Metallic Guidewires DE EP 15787824.0 Issued
NHLBI E-253-2014-0-EP-03 Segmented Metallic Guidewires EP National Stage 15787824.0 Issued
NCI E-294-2010-1-US-01 Pharmaceutical Composition Comprising Nanog SHRNA, and Method of Using Nanog SHRNA to Treat Cancer US CIP 14/886,970 9512429 Issued PDF
NHLBI E-253-2014-0-PCT-02 Segmented Metallic Guidewires PCT PCT PCT/US2015/056266 Expired
NIDDK E-284-2008-1-PCT-02 Combination Therapy of TSHR Antagonist and IGFR Inhibitor PCT PCT PCT/US2015/056178 Expired
NCI E-254-2005-2-CN-23 CODON OPTIMIZED IL-15 AND IL-15R-ALPHA GENES FOR EXPRESSION IN MAMMALIAN CELLS CN DIV 201510666821.3 Abandoned
NCI E-001-2016-0-US-01 Anti-CD30 Chimeric Antigen Receptors US 62/241,896 Abandoned
NIAAA E-316-2013-0-KR-12 Process for producing (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate KR National Stage 10-2015-7029333 Issued
NCI E-014-2016-0-US-01 Targeting Of Anti-HIV CD8 Cells To B-cell Follicles By Ectopic Expression Of CXCR5 US 62/241,658 Abandoned
NCI E-009-2016-0-US-01 Prime-boost Combination Vaccine To Expand Breadth of Immunological Response US 62/241,599 Abandoned
NCI E-242-2015-1-EP-04 Peptide-Based Methods For Treating Pancreatic Cancer EP National Stage 15788259.8 Issued
NCI E-242-2015-1-DE-01 Peptide-Based Methods For Treating Pancreatic Cancer DE EP 15788259.8 Issued
NCI E-242-2015-1-FR-01 Peptide-Based Methods For Treating Pancreatic Cancer FR EP 15788259.8 Issued
NCI E-242-2015-1-GB-01 Peptide-Based Methods For Treating Pancreatic Cancer GB EP 15788259.8 Issued
NCI E-242-2015-1-CH-01 Peptide-Based Methods For Treating Pancreatic Cancer CH EP 15788259.8 Issued
NCI E-242-2015-1-IE-01 Peptide-Based Methods For Treating Pancreatic Cancer IE EP 15788259.8 Issued
NCI E-242-2015-1-AU-02 Peptide-Based Methods For Treating Pancreatic Cancer AU National Stage 2015333728 Issued
NCI E-263-2009-0-US-09 Antiangiogenic Small Molecules and Methods of Use US CON 14/882,271 9504729 Abandoned PDF
NCI E-242-2015-2-US-01 Peptides Having Anti-Inflammatory Properties US CIP 14/882,293 9492499 Issued PDF
NCI E-242-2015-2-PCT-02 Peptides Having Anti-Inflammatory Properties PCT PCT PCT/US2015/055380 Expired
NCI E-242-2015-1-PCT-01 Peptide-Based Methods For Treating Pancreatic Cancer PCT PCT COMB PCT/US2015/055305 Expired
NCI E-242-2015-1-CA-03 Peptide-Based Methods For Treating Pancreatic Cancer CA National Stage 2964361 Pending
NCI E-263-2014-0-GB-09 Methods To Eliminate Cancer Stem Cells By Targeting CD47 GB EP 15788253.1 Issued
NCI E-263-2014-0-DE-07 Methods To Eliminate Cancer Stem Cells By Targeting CD47 DE EP 15788253.1 Issued
NCI E-263-2014-0-FR-08 Methods To Eliminate Cancer Stem Cells By Targeting CD47 FR EP 15788253.1 Issued
NCI E-263-2014-0-EP-05 Methods To Eliminate Cancer Stem Cells By Targeting CD47 EP National Stage 15788253.1 Issued
NCI E-034-2010-0-US-06 BETA-MANNOSYLCERAMIDE AND STIMULATION OF NKT CELL ANTI-TUMOR IMMUNITY US CON 14/879,476 9517243 Issued PDF